San Antonio Breast Cancer Symposium (SABCS)

The DEBBRAH trial met its primary endpoint of overall survival in a cohort of patients with HER2-positive or HER2-low advanced breast cancer and leptomeningeal carcinomatosis with positive cerebrospinal fluid cytology.

Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.

Data highlight the importance of genomic testing to help optimize treatment and reduce disparities for Black patients with hormone receptor–positive HER2-negative breast cancer, according to Sonya Reid, MD, MPH.

Trastuzumab emtansine plus tucatinib has promising clinical activity and a manageable safety profile in HER2-positive metastatic breast cancer, says Sara A. Hurvitz, MD.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

The pembrolizumab-based regimen in the phase 3 KEYNOTE-756 trial produces a larger pathologic complete response benefit in patients with node-positive disease and higher PD-L1 expression, according to Joyce O’Shaughnessy, MD.

Preclinical research supports the rationale of combining a BDC-1001 surrogate with pertuzumab to target HER2-expressing tumors.

A future planned analysis of the monarchE trial may further define how circulating tumor DNA dynamics can help identify patients with hormone receptor–positive HER2-negative breast cancer who are at high risk of recurrence.

Combining capivasertib with fulvestrant improves time to deterioration compared with placebo plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer in the CAPItello-291 trial.

Future-looking models see a large decrease in the cost of running sentinel lymph node assessments when artificial intelligence is used.

Combining ribociclib with endocrine therapy appears to be effective and tolerable for those with hormone receptor–positive HER2-negative advanced breast cancer, including elderly patients.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota discusses the incidence of complications and patient-reported outcomes associated with breast conservation therapy for multiple ipsilateral breast cancer.

An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.

Hypofractionated—large doses of radiation given over a shorter period of time than standard radiation—and conventional proton radiotherapy yielded comparable normal tissue sparing and complication rates postmastectomy in patients with breast cancer, according to findings from a recent study.

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

If feasible, hypofractionated radiation—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy would provide more patients with breast cancer a tissue-sparing option, according to an expert from the Mayo Clinic.

It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.

The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.

Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.

An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.

An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.

Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.

During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways.

Patients with HER2-positive metastatic breast cancer experienced promising preliminary safety and efficacy with trastuzumab deruxtecan alone and in combination with pertuzumab.

Improvements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.

Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.

Long-term findings from the phase 2 GeparOLA trial indicate that olaparib plus paclitaxel and carboplatin did not result in further benefit vs paclitaxel, and carboplatin for patients with HER2-negative, homologous recombination–deficient early breast cancer.

Robert Mutter, MD, of Mayo Clinic says that proton postmastectomy radiation therapy allows for excellent tissue sparing in the management of breast cancer.